Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Simultaneous quantification of antibody-RNA conjugates and the transcriptome by single cell RNA-sequencing

ABSTRACT: Simultaneous quantification of antibody-RNA conjugates and the transcriptome by single cell RNA-sequencing

PROVIDER: PRJNA476555 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7357190_1.fastq.gz	Fastqsanger.gz
	SRR7357190_2.fastq.gz	Fastqsanger.gz
	SRR7357191_1.fastq.gz	Fastqsanger.gz
	SRR7357191_2.fastq.gz	Fastqsanger.gz
	SRR7357192_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Simultaneous quantification of antibody-RNA conjugates and the transcriptome from fixed cells by RAID

Project description:Simultaneous quantification of antibody-RNA conjugates and the transcriptome from fixed cells by RAID

| PRJNA476554 | ENA

Simultaneous quantification of antibody-RNA conjugates and the transcriptome by single cell RNA-sequencing

Project description:Undifferentiated and differentiated Keratinocytes (AG1478 treated) were stained with antibody-RNA conjugates (targeting EGFR and ITGA6) to measure protein-based differentiation changes in conjunction with single-cell transcriptomics.

2019-02-13 | GSE115936 | GEO

Simultaneous quantification of antibody-RNA conjugates and the transcriptome from fixed cells by RAID

Project description:Undifferentiated and differentiated Keratinocytes (AG1478 treated) were stained with antibody-RNA conjugates to measure protein-based diffrentiation changes in conjunction with single-cell transcriptomics. The cells were crosslinked and stained according to the RAID procedure to allow intracellular immunostaining. Antibodies used in this experiment are (TGM1, NOTCH1, KLK6, JAG1, phospho-RPS6, phospho-FAK).

2019-02-13 | GSE115937 | GEO

Humanized antibody-drug conjugates for SSTR2-positive tumor treatment

Project description:Humanized antibody-drug conjugates for SSTR2-positive tumor treatment

| PRJNA1303643 | ENA

Humanized antibody-drug conjugates for SSTR2-positive tumor treatment

Project description:Somatostatin receptor 2 (SSTR2) is overexpressed in neuroendocrine tumors (NETs) and meningiomas. The objective of this study was to develop an SSTR2-targeted therapy to treat both tumor types. We engineered and humanized an anti-SSTR2 monoclonal antibody (mAb) demonstrating strong cancer cell binding, internalization in cancer cells, and tumor specificity, as evidenced by flow cytometry, confocal microscopy, and live-animal imaging. Antibody-drug conjugates (ADCs) were generated by conjugating the SSTR2 mAb with potent payloads, including monomethyl auristatin F (MMAF) or mertansine (DM1). In vitro assessments revealed high cytotoxicity across diverse NET subtypes and meningioma cell lines. In vivo efficacy was confirmed in two mouse models, i.e. subcutaneous NET xenografts and intracranial meningioma xenografts, where treatment inhibited proliferation, induced apoptosis and cell death, exhibited minimal toxicity, and extended survival. The mechanism of action was further elucidated through bulk RNA sequencing post-treatment. These findings highlight the therapeutic potential of our humanized SSTR2 mAb for targeted payload delivery in NETs and meningiomas.

2025-08-12 | GSE304978 | GEO

Immune-stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity

Project description:Immune-stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity

| PRJNA663153 | ENA

Low-input RNase footprinting for simultaneous quantification of cytosolic and mitochondrial translation

Project description:Low-input RNase footprinting for simultaneous quantification of cytosolic and mitochondrial translation

| PRJNA638017 | ENA

SNX10 deficiency confers resistance to anti-HER2 antibody-drug conjugates via regulating endosomal trafficking

Project description:Antibody-drug conjugates (ADCs) are a rapidly developing therapeutic approach in cancer treatment that has shown remarkable efficacy in breast cancer. Despite the promising efficacy of anti-HER2 ADCs, many patients are still experiencing disease progression under treatment. Here, by analyzing the transcriptome data from patient-derived organoid models, I-SPY2 trial, and resistant cell lines, we identified that SNX10 deficiency conferred anti-HER2 ADCs resistance. Low levels of SNX10 attenuated HER2 recycling and promoted HER2 trafficking into lysosomes. We also noticed that the lack of interaction between SNX10 and the transcription factor STAT1 inhibited its activation, while STAT1 binds to the promoter region of RAB11A and regulates its transcription. Thus, the lack of SNX10 inhibited HER2 recycling by downregulating RAB11A, decreased cell-surface HER2, and caused anti-HER2 ADC resistance.

2025-03-31 | GSE269495 | GEO

Simultaneous characterisation of RNA and protein subcellular dynamics

Project description:Existing methods to analyse RNA localisation are constrained to specific RNAs or subcellular niches, precluding the cell-wide mapping of RNA. We present Localisation of RNA (LoRNA), which maps, at once, RNAs to membranous (nucleus, ER and mitochondria) and membraneless compartments (cytosol, nucleolus and phase-separated granules). Simultaneous interrogation of all RNA locations allows the system-wide quantification of RNA proportional distribution and the comprehensive analysis of RNA subcellular dynamics. Moreover, we have re-engineered the LOPIT (Localisation Of Proteins by Isotope Tagging) method, enabling integration with LoRNA, to jointly map RNA and protein subcellular localisation. Applying this framework, we obtain a global re-localisation map for 31839 transcripts and 5314 proteins during the unfolded protein response, uncovering that ER-localised transcripts are more efficiently recruited to stress granules than cytosolic RNAs, and revealing eIF3d is key to sustain cytoskeletal function. Overall, we provide the most exhaustive map to date of RNA and protein subcellular dynamics.

2022-01-25 | PXD030456 | Pride

Immune-stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity I

Project description:Immune-stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity I

| PRJNA662959 | ENA